In a meta-analysis of 7 nonexperimental cohort studies, there was a positive, almost linear association with no evidence of a threshold between alcohol consumption at baseline and systolic blood pressure levels during follow-up in healthy persons.

Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

A greater than 15 mmHg reduction in 24-h ambulatory systolic BP was reported with the two highest single doses of the siRNA therapeutic zilebesiran, targeting hepatic angiotensinogen synthesis, at month 3 compared with placebo in the KARDIA 1 phase 2 trial.

ESC Congress 2023 The FRAIL-AF trial showed that frail older patients with AF who switched from VKA to a DOAC had a 69% higher risk of bleeding, compared with patients who continued using VKA. There was no difference between DOACs and VKA in stroke reduction in this patient population.

ESC Congress 2023 In a large pooled analysis, intravenous ferric carboxymaltose reduced the risk of CV hospitalizations or CV death combined, but not mortality alone, in patients with HFrEF/HFmrEF and iron deficiency.

ESC Congress 2023 The QUEST study demonstrates that qiliqiangxin, a mixture of 11 different herbs which is used in traditional Chinese medicine, reduces the risk of CV death or HF hospitalization in patients with HFrEF.

ESC Congress 2023 In HFrEF patients with iron deficiency, IV ferric carboxymaltose resulted in a modest albeit not statistically significant improvement in the hierarchical composite outcome of all-cause mortality, HF hospitalization, and change in exercise capacity.

ESC Congress 2023 STEP HFpEF showed that once-weekly semaglutide 2.4 mg improved HF-related symptoms, physical limitations and exercise function, and led to greater weight loss in patients with HFpEF and obesity, compared with placebo.

ESC Congress 2023 Well before the next scheduled full ESC guideline on HF, new evidence of several RCTs that should change the management of patients with HF has become available. Therefore, the 2023 Focused Update was presented and published.

ESC Congress 2023 New recommendations in the 2023 ESC guidelines for the management of CVD in patient with diabetes include focus on glucose-lowering medication with proven CV benefit and/or safety and the new SCORE2-Diabetes risk score.

ESC Congress 2023 In the RED-CVD trial, it was shown that a proactive diagnostic intervention strategy improves early diagnosis of CVD in primary care patients with COPD and/or T2D.